EX-1 2 a13-18362_1ex1.htm EX-1

Exhibit 1

 

JOINT FILING AGREEMENT

 

In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13D (including any amendments thereto) relating to the beneficial ownership of Common Stock, $0.0001 par value per share, of Trius Therapeutics, Inc. is being filed with the Securities and Exchange Commission on behalf of each of them. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

 

Dated: August 9, 2013

 

 

 

CUBIST PHARMACEUTICALS, INC.

 

 

 

 

By:

/s/ Thomas J. DesRosier

 

Nam:

Thomas J. DesRosier

 

Title:

Senior Vice President, Chief Legal Officer, General Counsel and Secretary

 

 

 

 

BRGO CORPORATION

 

 

 

 

By:

/s/ Thomas J. DesRosier

 

Nam:

Thomas J. DesRosier

 

Title:

Secretary

 


 

SCHEDULE I

 

DIRECTORS AND EXECUTIVE OFFICERS OF CUBIST AND PURCHASER

 

The name, business address and present principal occupation of each of the directors and executive officers of Cubist and Purchaser are set forth below.  Except as otherwise indicated, all of the persons listed below are citizens of the United States of America.  Directors are noted with an asterisk.

 

Cubist Directors and Executive Officers:

 

Name and Business Address

 

Present Principal Occupation

 

Name and Address of Corporation
or Other Organization (if different
from the address provided in
Column 1)

*Michael W. Bonney
Cubist Pharmaceuticals, Inc.
65 Hayden Ave
Lexington, MA 02421

 

Chief Executive Officer and Director of Cubist Pharmaceuticals, Inc.

 

 

 

 

 

 

 

Robert J. Perez, MBA
Cubist Pharmaceuticals, Inc.
65 Hayden Ave
Lexington, MA 02421

 

President and Chief Operating Officer of Cubist Pharmaceuticals, Inc.

 

 

 

 

 

 

 

Steven C. Gilman, Ph.D.
Cubist Pharmaceuticals, Inc.
65 Hayden Ave
Lexington, MA 02421

 

Executive Vice President, Research & Development and Chief Scientific Officer of Cubist Pharmaceuticals, Inc.

 

 

 

 

 

 

 

Thomas DesRosier, J.D.
Cubist Pharmaceuticals, Inc.
65 Hayden Ave
Lexington, MA 02421

 

Senior Vice President, Chief Legal Officer, General Counsel and Secretary of Cubist Pharmaceuticals, Inc.

 

 

 

 

 

 

 

Gregory Stea
Cubist Pharmaceuticals, Inc.
65 Hayden Ave
Lexington, MA 02421

 

Senior Vice President, Commercial Operations of Cubist Pharmaceuticals, Inc.

 

 

 

 

 

 

 

Michael Tomsicek, MBA
Cubist Pharmaceuticals, Inc.
65 Hayden Ave
Lexington, MA 02421

 

Senior Vice President and Chief Financial Officer of Cubist Pharmaceuticals, Inc.

 

 

 


 

Name and Business Address

 

Present Principal Occupation

 

Name and Address of Corporation
or Other Organization (if different
from the address provided in
Column 1)

Patrick Vink, M.D.(1)
Cubist Pharmaceuticals, Inc.
65 Hayden Ave
Lexington, MA 02421

 

Senior Vice President and General Manager of International Business of Cubist Pharmaceuticals, Inc.

 

 

 

 

 

 

 

*Kenneth M. Bate, MBA
Cubist Pharmaceuticals, Inc.
65 Hayden Ave
Lexington, MA 02421

 

Independent Consultant

 

 

 

 

 

 

 

*Mark H. Corrigan, M.D.(2)

 

President and Chief Executive Officer of Zalicus Inc.

 

Zalicus Inc.
245 First St.
Cambridge, MA 02142

 

 

 

 

 

*Jane Henney, M.D.
Cubist Pharmaceuticals, Inc.
65 Hayden Ave
Lexington, MA 02421

 

n/a

 

 

 

 

 

 

 

*Nancy J. Hutson, Ph.D.
Cubist Pharmaceuticals, Inc.
65 Hayden Ave
Lexington, MA 02421

 

n/a

 

 

 

 

 

 

 

*Alison Lawton

 

Chief Operating Officer of OvaScience, Inc.

 

OvaScience, Inc.
215 First St # 240
Cambridge, MA 02142

 

 

 

 

 

*Leon O. Moulder, Jr., MBA

 

Chief Executive Officer of TESARO, Inc.

 

TESARO, Inc.
1000 Winter Street

Suite #3300

Waltham, MA 02451

 

 

 

 

 

*Martin Rosenberg, Ph.D.

 

Chief Scientific Officer of Promega Corporation

 

Promega Corporation
2800 Woods Hollow Road
Madison, WI 53711

 

 

 

 

 

*J. Matthew Singleton, MBA, CPA
Cubist Pharmaceuticals, Inc.
65 Hayden Ave
Lexington, MA 02421

 

n/a

 

 

 

 

 

 

 

*Martin H. Soeters(3)

 

President of Novo Nordisk Europe A/S

 

Novo Nordisk, Inc.
Region Europe A/S
Thurgauerstrasse 36/38
CH-8050 Zurich
Switzerland

 

(1)  Mr. Vink is a citizen of the Netherlands.

 

(2)  Dr. Corrigan is a citizen of the United States, Ireland and Switzerland.

 

(3)  Mr. Soeters is a citizen of the Netherlands.

 


 

Name and Business Address

 

Present Principal Occupation

 

Name and Address of Corporation
or Other Organization (if different
from the address provided in
Column 1)

*Michael B. Wood, M.D.
Cubist Pharmaceuticals, Inc.
65 Hayden Ave
Lexington, MA 02421

 

Orthopedic Surgeon and retired President-emeritus of the Mayo Foundation and Professor of Orthopedic Surgery at the Mayo Clinic School of Medicine

 

Mayo Clinic
200 First Street SW
Rochester, MN 55905

 

Purchaser Directors and Executive Officers:

 

Name and Business Address

 

Present Principal Occupation

 

Name and Address of Corporation
or Other Organization (if different
from the address provided in
Column 1)

*Michael W. Bonney
Cubist Pharmaceuticals, Inc.
65 Hayden Ave
Lexington, MA 02421

 

Chief Executive Officer and Director of Cubist Pharmaceuticals, Inc.; President and Director of BRGO Corporation

 

 

 

 

 

 

 

*Thomas DesRosier, J.D.
Cubist Pharmaceuticals, Inc.
65 Hayden Ave
Lexington, MA 02421

 

Senior Vice President, Chief Legal Officer, General Counsel and Secretary of Cubist Pharmaceuticals, Inc.; Secretary and Director of BRGO Corporation

 

 

 

 

 

 

 

*Michael Tomsicek, MBA
Cubist Pharmaceuticals, Inc.
65 Hayden Ave
Lexington, MA 02421

 

Senior Vice President and Chief Financial Officer of Cubist Pharmaceuticals, Inc.; Treasurer and Director of BRGO Corporation

 

 

 


 

SCHEDULE II

 

Shares of Common Stock of Trius Therapeutics, Inc. Beneficially Owned by Stockholders

 

Row

 

Stockholder

 

Shares Owned

 

Shares issuable upon
exercise of outstanding
options

 

 

 

 

 

 

 

1

 

Neil Abdollahian

 

17,404

 

175,428

2

 

Brian G. Atwood

 

0

 

60,302

3

 

Kenneth Bartizal, Ph.D.

 

95,300

 

227,964

4

 

Karin Eastham

 

18,114

(1)

62,441

5

 

John Finn, Ph.D.

 

169,011

(2)

317,788

6

 

Seth H. Z. Fischer

 

0

 

32,500

7

 

InterWest Partners IX, LP

 

3,548,643

 

0

8

 

David S. Kabakoff, Ph.D.

 

111,366

(3)

75,000

9

 

Nina Kjellson

 

0

 

60,302

10

 

Michael Morneau

 

12,545

 

125,000

11

 

Brenda O’Leary, Ph.D.

 

21,302

 

51,000

12

 

Matthew Onaitis

 

0

 

100,000

13

 

Philippe Prokocimer, M.D.

 

92,887

(4)

308,313

14

 

Karen Potts

 

348

 

113,159

15

 

Prism Venture Partners V, L.P.

 

2,032,600

 

0

16

 

Prism Venture Partners V-A, L.P.

 

925,630

 

0

17

 

John P. Schmid

 

107,639

 

336,858

18

 

Theodore R. Schroeder

 

0

 

66,116

19

 

Karen Joy Shaw

 

28,867

 

112,500

20

 

Jeffrey Stein, Ph.D.

 

210,457

(5)

994,069

21

 

J. Craig Thompson

 

1,344

 

365,000

22

 

Paul Truex

 

11,270

(6)

63,403

23

 

Versant Side Fund III, L.P.

 

18,997

 

0

24

 

Versant Venture Capital III, L.P.

 

3,216,842

 

0

 

(1) Includes 12,114 shares owned by The Karin Eastham Defined Benefit Plan, of which Karin Eastham is a trustee.

(2) Includes 166,860 shares owned by The John and Deborah Finn Trust, of which John Finn is a trustee.

(3) Includes 53,101 shares owned by The David S. and Susan O. Kabakoff Family Trust, of which David Kabakoff is the trustee; and 5,285 shares owned by Strategy Advisors, LLC Defined Benefit Plan, of which David Kabakoff is plan administrator.

(4) Includes 82,022 shares owned by Philippe and Maria Prokocimer Family Trust.

(5) Includes 210,457 shares owned by The Jeff Stein and Catherine Naughton Revocable Trust.

(6) Includes 11,270 shares owned by The 2002 Truex Family Trust u/d/t April, 20 2005, of which Paul Truex is a trustee.